The same biochemical triggers that spur a “fight or flight” response when we encounter threats may help tumor cells to thrive.
Roswell Park's Assistant Professor of Oncology, Shipra Gandhi, MD, and Hematology-Oncology Fellow, Manu Pandey, MBBS discuss the results of the first prospective clinical trial to show that the beta-blocker propranolol is safe in combination with pembrolizumab, an immunotherapy also known as Keytruda that has become standard therapy for patients newly diagnosed with advanced or metastatic melanoma. The researchers also document preliminary evidence that these two drugs work together to engage the immune system against tumor cells.
Related Presenters
Related Videos
